Orthex Corporation: Proposals of the Shareholders’ Nomination Board to the Annual General Meeting 2026

Orthex’s Shareholders’ Nomination Board proposes expanding the Board from five to six members at the AGM on 14 April 2026, re-electing four incumbents and adding Sari Somerkallio (ex-Fiskars/FSecure CFO) and David Miller (Investment Director at Conficap). Remuneration is unchanged (Chair EUR 4,000/month; other members EUR 2,000/month; meeting fees EUR 250/500), and Miller is noted as not independent of major shareholders due to a service agreement with Conficap, which holds 14% of shares. The proposals were unanimous and reference compliance with the Finnish Corporate Governance Code; Orthex reported net sales of EUR 89.7m in 2024.

Analysis

Market structure: Board changes at Orthex (net sales €89.7m in 2024) principally alter corporate governance not product-market supply/demand. Immediate winners are Conficap (14% holder) and minority shareholders if governance enables M&A or capital returns; losers are management optionality and any incumbent strategy opponents. Expect modest equity re-rating potential (order of +10–30% upside if a transaction/strategic program is delivered within 12–18 months), negligible direct FX or commodity impact and small tightening in implied credit risk for any third‑party financings.

Risk assessment: Tail risks include a shareholder conflict or litigation (share price -20–40%), or a governance stalemate that delays execution; operational risk from board composition change is low. Time horizons: immediate (days) — light trading reaction; short-term (weeks/months) — AGM on 14 Apr 2026 is catalyst; long-term (12–24 months) — higher probability of M&A, divestment, or buyback. Hidden dependency: David Miller’s Conficap link raises potential for shareholder-driven transactions that may favor the majority holder; monitor related-party transaction disclosures.

Trade implications: Primary direct play — establish a modest 2–3% long position in ORTHEX (Nasdaq Helsinki ORTHEX) before the AGM, target +30% in 12 months, hard stop -20%. Relative trade — pair long ORTHEX vs short Fiskars (FIS1V:HEL) 1:1 to isolate governance premium; size 1% net exposure. Options — if liquid, buy Apr–Dec 2026 call spreads (ATM to +15–25%) to limit capital and express a 6–12 month event view. Rebalance after AGM and any Conficap stake moves.

Contrarian angles: Consensus may underweight the probability of a value‑realizing corporate action; historically small Nordic family-backed firms with ~10–20% strategic stakes have >30% chance of eventual sale/takeover within 24 months. Reaction is likely underdone if Conficap increases above 20% (trigger for more aggressive acquisitive or tender actions). Unintended consequence: board expansion could slow execution—reduce exposure if no transaction path emerges by Q4 2026.

Key Decisions for Investors

• Establish a 2–3% long position in ORTHEX (ORTHEX:HEL) within 30 days ahead of the AGM (14 Apr 2026); set target +30% within 12 months and stop-loss at -20%.
• Enter a pair trade: long ORTHEX (1%) vs short Fiskars (FIS1V:HEL) (1%) to capture governance/activation upside while hedging sector risk; review after AGM and trim if 50% of target achieved.
• If listed options are available, buy a 6–12 month call spread on ORTHEX (ATM to +15–25% strikes) sized to ~1% notional exposure to limit downside; alternatively use an equity swap if options illiquid.
• Increase position to 4–6% or prepare for a takeover-style exit if Conficap’s reported holding rises above 20% within 90 days (monitor shareholder register weekly); reduce position by 50% if no clear strategic path by 31 Dec 2026.